[{"id":"fd1aa0c0-bae7-44e0-b6d3-6aaebbda9e73","acronym":"TAK-007-2001","url":"https://clinicaltrials.gov/study/NCT05020015","created_at":"2021-08-25T14:53:09.103Z","updated_at":"2025-02-26T06:48:42.647Z","phase":"Phase 2","brief_title":"A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)","source_id_and_acronym":"NCT05020015 - TAK-007-2001","lead_sponsor":"Takeda","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TAK-007"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 11/12/2021","start_date":" 11/12/2021","primary_txt":" Primary completion: 10/14/2025","primary_completion_date":" 10/14/2025","study_txt":" Completion: 06/20/2030","study_completion_date":" 06/20/2030","last_update_posted":"2024-05-29"}]